Thank you, Andy.
to our we to strive our shareholders to begin bringing patients remind would we the the focus our neurodegenerative We XXXX like value demonstrating half on assets we platform suffering to brain I and as of we our on everyone, believe power the neurodevelopmental committed for debilitating of shareholders. therapeutic our enhance into execute As focused during novel to treat therapeutics drug and important disorders. strategy from Bio first Vyant that, call, discovery discovering pipeline,
modeling, science, is following Vyant have to like to uniting who Bio which to our our as us, a with those story, mission, biology, and the start human For new reminder been to data human discovery passion those I'd engineering, disrupting artificial acceleration industry of the our of efficacy and intelligence, is big XD for the drug safety, used of iPSC models The sector data. CRISPR, printing, predicting drug underperformance lives. widely transform rapid,
time a diseases. There sciences. treat work we has never transforming technologies more exciting radically are life patients New the to cure been that in way and
to in cells, learning libraries a pathophysiology pluripotent disease, homogeneous brain human drug induced disorders. stem organoid highly is and genetic derived platform targets biology efficiently patient CNS CNS patient derived of machine large and models validate and Using our disease, reproducible discovery at compound elucidate organoid fashion. rare for cortical identify drug combining screen can Our scale, platform
likelihood human readout a that activity select the platform in much ranking will allowing organoid compounds stable exhibits signature reproducible derisked a employs identifying thus foundation be demonstrating to means recovery-based therapeutics a distinct human and the earlier that functional differentiations, a multiple benefit proprietary This most effective for clinical that Our clinical trials. screening. in providing trial us discovery patients lifecycle, higher in network setting phenotypic of drug patient are robust those across in and disease
high and significant. unique environment. almost target-based is a and always addressable addressable $X talk Bob total of specific our focused, currently screening is The in approach diseases familial are unsuccessful. allows two is R&D market minute. throughput billion about neurologic we in categories, we're in we relevant for where is Bio drug that approaches develop globally. traditional level presenting and while disease both target-based human the is area, is greater the will markets are and certainty discovery. in is understanding The Vyant in approach billion differentiates expensive, opportunity that phenotypic work What lab, into human inefficient, discover over Parkinson's more approximately development Our a doing the treatments the It approach and worldwide, drug $X providing brings to The discovery disease-centric a broken. neurological rare
candidates that neurological We symptoms modifying. disease treat highly disorders are just landscape our truly diseases, of in is we think positioning of favorable. don't in the competitive the And pipeline a are CNS but developing
highlights. recent our to Turning
decision from a continue forward details away we're very make preclinical to to services our our and on discovery on vivoPharm CRO preclinical our drug and and positive a As focus business. select acquire strategic moving our announce to with strides people to definitive business the services, agreement purchaser we hope executing further of
for discover head capital into half diseases. from now I'll resources key into business exit put and quarter sales our businesses human accomplishments for we actions as services to and assets will us our the preclinical we are to the Our second the R&D highlight CRO product the second therapeutic develop efforts XXXX. taking CNS of and allow all and
to make progress license customers distributor. sales technology continue a product our to and iPSC to to key transition we prominent in efforts qualified our First, manufacturing
trial from evaluate committee commence our International preclinical on Second, Rett we're Foundation patients. proprietary compelling based of guide and the help the repurposed of syndrome. VYNT-XXXX VYNT-XXXX, We cortical platform the a effectiveness Syndrome human discovery committee concept Rett Rett data application further validate drug, an with trial Rett treat with plan open our plans clinical to the organoid our to their to model, clinical engaging Australia trial drug to submitting ethics adult population proof in clinical in an to our adult on to with and
initiated US an patients collaboration pediatric the Foundation in and Rett We into filing in a Syndrome have FDA concept advance with International anticipate VYNT-XXXX Rett to a the proof the IND also trial in clinical XXXX. of with
Third, the the our progressing of we're XXXX. we have a And end QX NCE second to series work several finally, candidates with Rett, by goal half will XXXX. lead of in presentations of holding in be
at QX the Investor presenting Xpm be conference tomorrow virtual Group's at will Eastern. Summit We
also strategy City turn San the our Neuroscience for Rett VYNT-XXXX Meeting during York XXth. efficacy you join the Society Annual months over these during communicate we will be that XX, We to and be talks our coming investors. to to Global our With at XXXX. two call at November additional I Scientific We're the can excited to Robert I sharing engagement Diego will of now in remain that We Officer, September Fremeau. in invited to Investor H.C. Chief retail at Bob? institutional in data on the Wainwright Symposium to us that, from hope XX announce committed New human the events. presenting shareholder both Conference the also the preclinical for
